By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Lonza Biologics Inc. 

101 International Drive

Portsmouth  New Hampshire  03801  U.S.A.
Phone: 603-334-6100 Fax: 603-334-6262


Who we are
Lonza Biologics Inc. in Portsmouth, New Hampshire, is part of the Lonza Group headquartered in Basel, Switzerland, a leading participant in the global biotechnology industry since 1980.

Where we are
Portsmouth, NH is a historic town of approximately 21,000 people, located North of Boston. Portsmouth, New Hampshire is located on the seacoast of New Hampshire with easy access to Boston, the White Mountains, Lakes and Maine.

What we do
The production site in Portsmouth has significant expertise in the field of mammalian cell culture and cGMP custom manufacturing and is active in the large-scale production of biopharmaceuticals.

Concretely, Portsmouth is a custom manufacturer of therapeutic monoclonal antibodies and recombinant proteins using mammalian cell culture for mammalian biopharmaceutical.

The facility has been in cGMP manufacture since 1996 and is dedicated to meeting the needs of our customers. The setup and performance of projects teams with experts from Lonza and our customers working together is unmatched in the industry.
With global operations, Lonza is the world’s leading contract manufacturer of monoclonal antibodies and recombinant proteins and vaccine targets. We undertake highly specialized development and manufacturing services for the pharmaceutical and biotechnology industries based on more than 20 years of experience in mammalian cell culture and proprietary technology for large-scale manufacture of innovative biopharmaceutical products.

We have contracts with many of the largest pharmaceutical companies in the world, and have customers ranging from international pharmaceutical companies and large biotechnology companies to emerging biotechnology companies.

Lonza is able to provide a complete development package, taking a product from vector construction and cell line development through to full-scale manufacture, including a full range of analytical services and regulatory support for clinical trials and in market supply.

Why work at Lonza?
Working at Lonza means interacting with intelligent and empowered people who focus on emerging technologies that are groundbreaking, exciting, and have a positive impact on humankind. If you like a fast-paced environment, a company without burdensome bureaucracy, and the ability to be involved in many aspects of internal and external business, we think you will like working at Lonza.

We know that our people are the cornerstone of our success. Lonza employees come from different countries, backgrounds, and cultures. If you join us, you will be rewarded for a job well done, you will have opportunities to develop your knowledge and skills, and you will be respected and valued.

What is it like to work at Lonza’s New England facilities?
The Portsmouth site is experiencing aggressive growth, both in our physical plant and in the size of our staff. Our environment is rapidly changing with a constant emphasis on finding innovative and better ways of providing our customers with products and services that are of exceptional quality, delivered on time, and exceed their expectations. We understand that every position in our company is critical in achieving this mission. We know that working together as a team requires mutual respect and accountability to each other.

Please visit us at to learn more.




CEO: Richard Ridinger

CFO: Toralf Haag


Please click here for Lonza job opportunities.

Key Statistics

Ownership: Public

Web Site: Lonza Biologics
Symbol: LONN.VX

Company News
Active Pharmaceutical Ingredient Maker Lonza Biologics (LONN.VX) to Hire 70 in New Hampshire 8/22/2016 7:25:47 AM
Proposed Lonza Biologics (LONN.VX) Expansion Could Mean 400 New Jobs at New Hampshire Manufacturing Site 2/16/2016 7:51:54 AM
Sunshine Biopharma, Inc. Signs Agreement With Lonza Biologics Inc. (LONN.VX) To Manufacture Its Lead Anti-Cancer Compound, Adva-27a 11/20/2014 8:42:07 AM
Lonza Biologics Inc. (LONN.VX) Lays Off 200 in MA 7/29/2013 8:17:19 AM
Genesis Biopharma, Inc. and Lonza Biologics Inc. Partner to Develop Contego™ 7/25/2011 6:26:53 AM
U.S.FDA Approves ORENCIA(R) (abatacept) Supplemental Biologics License Application (sBLA) For Third-Party Manufacturing Facility Lonza Biologics Inc. 5/8/2006 10:18:40 AM
Isotechnika Inc. Signs Manufacturing Agreement With Lonza Ltd.10/19/2005 5:11:38 PM
Transkaryotic Therapies, Inc. (TKT) (TKTX) Announces Manufacturing Agreement For Dynepo10/19/2005 5:11:25 PM
Lonza's L-Carnipure L-Carnitine Increases Fatty Acid Oxidation10/19/2005 5:11:19 PM
Lonza Group Files Patent Infringement Lawsuit Against Nutraceutical International Corporation10/19/2005 5:10:52 PM